Three-dimensional tumor models and genomic profiling for pediatric brain tumors
Official title: Preliminary Study With Biological Samples, Single-center, Non-profit, to Identify Biological Mechanisms and Resistance to Therapies in Three-dimensional Models Derived From Brain Tumors in Pediatric Patients.
Run by Meyer Children's Hospital IRCCS · NCT07417072 · Data updated 2026-11-12
This project will use tumor tissue and blood from children aged 3–18 undergoing neurosurgery to build 3D tumor models and run advanced genomic tests to see if they better characterize tumors and help guide personalized treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 3 Years to 18 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Meyer Children's Hospital IRCCS Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Florence, Firenze) |
| Status | Recruiting |
| Started | October 21, 2025 |
| Main results expected | June 2026 |
| Study ends | October 2026 |
| Registry record updated | February 18, 2026 |
| Trial ID | NCT07417072 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 3–18 with suspected brain tumors who are treatment‑naive, scheduled for neurosurgery, and whose legal guardians provide informed consent are ideal candidates.
✕Probably not a fit
Patients later found to have non‑neoplastic brain conditions, those with insufficient tissue or blood for analysis, or those who received prior systemic anticancer therapy are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The project collects tumor tissue and peripheral blood from treatment‑naive children aged 3–18 at the time of planned neurosurgery. Samples will undergo third‑generation sequencing and comprehensive genomic and epigenetic analyses to identify tumor alterations and germline information. Patient‑derived three‑dimensional tumor models will be generated to study biology and perform preclinical drug response testing. The integrated dataset aims to support personalized therapeutic strategies and improve preclinical evaluation pipelines for pediatric brain tumors.
Why it matters
Potential benefit: If successful, this approach could reveal actionable genetic alterations and provide personalized preclinical models to help choose more effective therapies for children with brain tumors.
How similar studies have gone: Genomic profiling and patient‑derived 3D models have shown promise in preclinical work and some adult and pediatric cohorts, but fully integrated personalized pipelines for pediatric brain tumors remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 3-18 years with suspected brain tumours undergoing neurosurgery * No previous bone marrow transplants or other haematological procedures that could potentially interfere with germline analysis. * Patients who have not received any systemic anticancer treatment (including chemotherapy, radiotherapy or targeted therapies) prior to enrolment surgery. * Signature of informed consent Exclusion Criteria: * Subsequent histological confirmation of non-neoplastic brain pathology (e.g. malformations, inflammatory lesions, demyelinating processes). * Insufficient quantity or quality of tumour tissue or peripheral blood for the analyses required by the protocol. * Presence of serious clinical conditions, systemic infections or haemodynamic instability that contraindicate the collection of biological samples or inclusion in the study.
Where it's running
-
Meyer Children's Hospital IRCCS
Florence, Firenze, Italy Recruiting
Study contacts
- Study coordinator: Iacopo Sardi
- Email: iacopo.sardi@meyer.it
- Phone: 0555662631
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
KLF4 Epigenetic Modulation in Colorectal Tissue
Researchers will look at how the KLF4 gene’s methylation changes as colorectal tissue moves from polyps to more advanced lesions to see if this reflects or relates to gene activity.
-
Registry of pediatric proton and photon radiation therapy
This registry will collect detailed 3D radiation dose data and health outcomes from children and young adults treated with proton or photon therapy to see how treatment type relates to long-term side effects and quality of life.
-
Using blood markers to improve treatment for metastatic pancreatic cancer
This study is testing if analyzing certain blood markers can help doctors better tailor treatments for patients with advanced pancreatic cancer starting a specific chemotherapy regimen.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.